Clinical Research Directory
Browse clinical research sites, groups, and studies.
HANDLE-a Real World Study on Satralizumab in NMOSD
Sponsor: Huashan Hospital
Summary
This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.
Official title: A Real-World Practical Model of Integrated Management for Chinese Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) on Satralizumab
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2025-03-31
Completion Date
2027-06-30
Last Updated
2025-03-18
Healthy Volunteers
No
Interventions
Satralizumab
Satralizumab is the first monoclonal antibody approved for the treatment of NMOSD in China. Currently, there is still a lack of standard patient management pattern for NMOSD. While satralizumab offers the advantage of home administration, there remains a pressing need for optimized patient management.
Locations (1)
Huashan Hospital
Shanghai, Shanghai Municipality, China